An Open Label Randomized Phase 2 Study To Evaluate The Activity, Tolerability, And Toxicity Of Combined Neoadjuvant Anti-Angiogenesis and Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy.

Trial Profile

An Open Label Randomized Phase 2 Study To Evaluate The Activity, Tolerability, And Toxicity Of Combined Neoadjuvant Anti-Angiogenesis and Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Squalamine (Primary) ; Bicalutamide; Leuprorelin
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Dec 2011 Actual patient number (0) added as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Planned end date (1 Jun 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top